Related Experiment Video

Updated: Jul 17, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

LRIG inhibitors of growth factor signalling - double-edged swords in human cancer?

Håkan Hedman1, Roger Henriksson

  • 1Department of Radiation Sciences, Oncology, Umeå University, SE-90187 Umeå, Sweden. hakan.hedman@onkologi.umu.se

European Journal of Cancer (Oxford, England : 1990)
|January 24, 2007
PubMed

Insights

Leucine-rich repeats and immunoglobulin-like domains (LRIG) proteins regulate growth factor signalling. Depending on the cellular context, LRIG proteins may promote or suppress human cancer, acting as double-edged swords.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Signalling

Background:

  • Leucine-rich repeats and immunoglobulin-like domains (LRIG) proteins are identified as negative regulators of growth factor signalling.
  • These proteins are hypothesized to function as tumour suppressors by inhibiting growth factor receptor signalling through ubiquitylation and degradation.
  • Emerging data on LRIG expression in human cancers present conflicting evidence regarding their tumour suppressor roles.

Purpose of the Study:

  • To review the current understanding of LRIG proteins in cancer.
  • To evaluate the dual role of LRIG proteins in human cancer based on cellular context.
  • To reconcile inconsistent findings regarding LRIG proteins as tumour suppressors.

Main Methods:

  • Literature review of studies on LRIG protein function and expression in cancer.
  • Analysis of existing data on growth factor signalling pathways.
  • Examination of ubiquitylation and degradation mechanisms of growth factor receptors.

Main Results:

  • LRIG proteins antagonize growth factor signalling by interacting with and promoting the degradation of growth factor receptors.
  • Accumulating clinical data suggest LRIG proteins do not consistently act as tumour suppressors across all human cancers.
  • The function of LRIG proteins in cancer appears to be context-dependent.

Conclusions:

  • LRIG proteins exhibit context-dependent roles in human cancer.
  • LRIG proteins may function as "double-edged swords," capable of both promoting and suppressing cancer progression.
  • Further research is needed to elucidate the precise mechanisms underlying the dual role of LRIG proteins in different cellular environments.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...